首页> Journal of the American Academy of Dermatology> Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).

导出原文传递

翻译打印收藏纠错

第一作者： Brett,King

第一单位： Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.king@yale.edu.

作者： Brett,King ^[1] ; Maryanne M,Senna ^[2] ; Natasha A,Mesinkovska ^[3] ; Charles,Lynde ^[4] ; Matthew,Zirwas ^[5] ; Catherine,Maari ^[6] ; Vimal H,Prajapati ^[7] ; Sheetal,Sapra ^[8] ; Pawel,Brzewski ^[9] ; Lawrence,Osman ^[10] ; Sameh,Hanna ^[11] ; Marni C,Wiseman ^[12] ; Colleen,Hamilton ^[13] ; James,Cassella ^[13]

作者单位： Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.king@yale.edu. ^[1] Department of Dermatology, Lahey Hair Loss Center of Excellence, Lahey Hospital and Medical Center, Burlington, Massachusetts. ^[2] Department of Dermatology, University of California, Irvine, California. ^[3] Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Lynderm Research Inc., Probity Medical Research, Markham, Ontario, Canada. ^[4] DOCS Dermatology, Columbus, Ohio. ^[5] Faculty of Medicine, Department of Medicine, University of Montreal, Montreal, Quebec, Canada. ^[6] Division of Dermatology, Department of Medicine, and Sections of Community Pediatrics and Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Dermatology Research Institute, Probity Medical Research, Skin Health & Wellness Centre, Calgary, Alberta, Canada. ^[7] Institute of Cosmetic and Laser Surgery, Oakville, Ontario, Canada. ^[8] Department of Dermatology, Jagiellonian University, Krakow, Poland. ^[9] Quest Dermatology Research, Northridge, California. ^[10] Department of Medicine, Division of Dermatology, University of Toronto, Toronto, Ontario, Canada; Dermatology On Bloor, Toronto, Ontario, Canada. ^[11] Section of Dermatology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. ^[12] Sun Pharmaceutical Industries, Inc., Lexington, Massachusetts. ^[13]

关键词 Janus kinase (JAK) inhibitor Phase 3 Severity of Alopecia Tool (SALT)THRIVE-AA1 alopecia areata deuruxolitinib